Roche and High Throughput Genomics Partner for Advanced Gene Expression Analysis Solution.MADISON, Wis. -- Roche NimbleGen (SWX SWX Swiss Exchange (trademark of SWX Swiss Exchange)
SWX SolidWorks (3D solid modeling CAD software)
SWX Splitter / Wave Division Multiplexer :RO)(SWX:ROG ROG Roger
ROG Rouge (Everquest)
ROG Republic of Gamers
ROG Royal Observatory Greenwich (UK)
ROG Reactive Organic Gas
ROG Receipt Of Goods
ROG Rise Off Ground )(Pink Sheets:RHHBY) and High Throughput Genomics, Inc. (HTG HTG
In currencies, this is the abbreviation for the Haitian Gourde.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ), provider of the quantitative Nuclease Protection Assay A nuclease protection assay is a laboratory test used in biochemistry and genetics to identify individual RNA molecules in a heterogeneous RNA sample extracted from cells. The technique can identify one or more RNA molecules of known sequence even at low total concentration. (qNPA), have entered into a supply agreement. Under the agreement, Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis.
HTG will apply the company's quantitative nuclease protection assay (qNPA) process to the microarrays to enable researchers to quickly and efficiently measure the gene expression levels in a variety of sample types. The agreement enhances HTG's existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high density microarray providing in depth gene expression information.
"HTG's agreement with Roche NimbleGen affords us the opportunity to provide our customers with customizable content and an attractive sample preparation and processing format. Compared with other vendors, Roche NimbleGen was able to offer us unique and differentiated array synthesis and formatting capabilities that best meet our client needs," said T.J. Johnson, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , HTG. "The combination of low cost, flexibility, and high throughput means HTG's customers can derive substantial benefits quickly and we can increase the plex in the analysis process as needed as needed prn. See prn order. ."
Gerd Maass, CEO of Roche NimbleGen said, "The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high density arrays provide."
For more information on Roche NimbleGen microarrays, go to www.nimblegen.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression , inflammation, metabolism and CNS See Continuous net settlement.
See continuous net settlement (CNS). . Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice solstice (sŏl`stĭs) [Lat.,=sun stands still], in astronomy, either of the two points on the ecliptic that lie midway between the equinoxes (separated from them by an angular distance of 90°). Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
HTG's qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target evaluation; HTS HTS Heights
HTS Harmonized Tariff System
HTS High Throughput Screening (biomolecular assay screening)
HTS High-Throughput Screening (Pharmaceutical Industry)
HTS Harmonized Tariff Schedule lead optimization, metabolism and toxicology. HTG's platform is highly flexible and designed automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic extraction or target amplification. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
All trademarks used or mentioned in this release are protected by law.
NIMBLEGEN is a trademark of Roche.